322 results on '"Terenziani M"'
Search Results
2. Current practices of follow-up programs for childhood cancer survivors in Italy
- Author
-
Terenziani, M, Tozzi, A, Diaco, L, Biasin, E, Cattoni, A, Croci, I, Fraschini, D, Giorgiani, G, Haupt, R, Muraca, M, Pillon, M, Sironi, G, Valsecchi, M, Mastronuzzi, A, Terenziani, Monica, Tozzi, Alberto Eugenio, Diaco, Laura, Biasin, Eleonora, Cattoni, Alessandro, Croci, Ileana, Fraschini, Donatella, Giorgiani, Giovanna, Haupt, Riccardo, Muraca, Monica, Pillon, Marta, Sironi, Giovanna, Valsecchi, Maria Grazia, Mastronuzzi, Angela, Terenziani, M, Tozzi, A, Diaco, L, Biasin, E, Cattoni, A, Croci, I, Fraschini, D, Giorgiani, G, Haupt, R, Muraca, M, Pillon, M, Sironi, G, Valsecchi, M, Mastronuzzi, A, Terenziani, Monica, Tozzi, Alberto Eugenio, Diaco, Laura, Biasin, Eleonora, Cattoni, Alessandro, Croci, Ileana, Fraschini, Donatella, Giorgiani, Giovanna, Haupt, Riccardo, Muraca, Monica, Pillon, Marta, Sironi, Giovanna, Valsecchi, Maria Grazia, and Mastronuzzi, Angela
- Abstract
Introduction: Quality of life in childhood cancer survivors is largely affected by survivorship care and transition from treatment to long-term follow-up (LTFU). Referring to evidence-based recommendations, we wanted to evaluate LTFU care for survivors through a survey among the Italian Association for Pediatric Hematology-Oncology (AIEOP) centers. The project aimed to evaluate the availability of services in Italy, investigate strengths and weaknesses, analyze improvements of awareness in the field, and identify the gaps that need to be addressed by different centers. Methods: Together with the family representatives, on behalf of AIEOP’s Late Effects Working Group, we developed a questionnaire on assisting childhood cancer survivors. All AIEOP centers received one questionnaire including information on local health system organizations; LTFU for childhood cancer survivors; services for adult survivors of childhood cancer; information provided to survivors/caregivers and care plan delivery. Results: Forty-eight AIEOP centers were contacted and 42 replied, with a response rate of 87.5%. The majority of respondents confirmed their interest in assisting patients with a survivorship care plan (95.2%), regardless of a clinic or dedicated staff. Discussion: This is the first overview of LTFU in Italy, which provides detailed results at national levels, prompting consideration of improvements in the last decade. Although there is a high level of interest in survivorship care, many centers lack resources to implement such programs. The identification of these challenges is useful for planning future strategies.
- Published
- 2023
3. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
- Author
-
Hurkmans, E. G. E., Klumpers, M. J., Dello Russo, Cinzia, De Witte, W., Guchelaar, H. -J., Gelderblom, H., Cleton-Jansen, A. -M., Vermeulen, S. H., Kaal, S., van der Graaf, W. T. A., Flucke, U., Gidding, C. E. M., Schreuder, H. W. B., de Bont, E. S. J. M., Caron, H. N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Mccowage, G., Nagabushan, S., Limaye, A., Rose, V., Catchpoole, D., Jorgensen, A. L., Barton, C., Delaney, L., Hawcutt, D. B., Pirmohamed, M., Pizer, B., Coenen, M. J. H., te Loo, D. M. W. M., Dello Russo C. (ORCID:0000-0002-2538-3832), Hurkmans, E. G. E., Klumpers, M. J., Dello Russo, Cinzia, De Witte, W., Guchelaar, H. -J., Gelderblom, H., Cleton-Jansen, A. -M., Vermeulen, S. H., Kaal, S., van der Graaf, W. T. A., Flucke, U., Gidding, C. E. M., Schreuder, H. W. B., de Bont, E. S. J. M., Caron, H. N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Mccowage, G., Nagabushan, S., Limaye, A., Rose, V., Catchpoole, D., Jorgensen, A. L., Barton, C., Delaney, L., Hawcutt, D. B., Pirmohamed, M., Pizer, B., Coenen, M. J. H., te Loo, D. M. W. M., and Dello Russo C. (ORCID:0000-0002-2538-3832)
- Abstract
Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value <10-5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5-2.7), p-value 5.0 × 10-7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.
- Published
- 2023
4. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
- Author
-
Hurkmans, E.G.E., Klumpers, M.J., Dello Russo, C., Witte, W. de, Guchelaar, H.J., Gelderblom, H., Cleton-Jansen, A.M., Vermeulen, S.H., Kaal, S., Graaf, W.T.A. van der, Flucke, U., Gidding, C.E.M., Schreuder, H.W.B., Bont, E.S.J.M. de, Caron, H.N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., McCowage, G., Nagabushan, S., Limaye, A., Rose, V., Catchpoole, D., Jorgensen, A.L., Barton, C., Delaney, L., Hawcutt, D.B., Pirmohamed, M., Pizer, B., Coenen, M.J.H., and Loo, D.M.W.M. te
- Subjects
Pharmacology ,Settore BIO/14 - FARMACOLOGIA ,TSPAN5 ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,cisplatin ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10] ,ototoxicity ,All institutes and research themes of the Radboud University Medical Center ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,carboplatin ,Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ,childhood cancer ,GWAS ,Pharmacology (medical) ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value −5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5–2.7), p-value 5.0 × 10−7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.
- Published
- 2023
5. TREATING LYMPHOMA IN THE PANDEMIC ERA: WHAT WE LEARNED FROM OUR EXPERIENCE AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
- Author
-
Gattuso, G., primary, Biassoni, V., additional, Podda, M., additional, Meazza, C., additional, Chiaravalli, S., additional, Nigro, O., additional, Sironi, G., additional, Livellara, V., additional, Puma, N., additional, Bergamaschi, L., additional, Terenziani, M., additional, Spreafico, F., additional, Massimino, M., additional, and Schiavello, E., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients
- Author
-
Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., Frappaz D., Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., and Frappaz D.
- Abstract
Introduction: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4 Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36 Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. Methods: We gathered non-metastatic patients over 18 years old (median age 28 years, range 18–48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996–2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. Results: Forty-four adults were considered (median follow-up 101 months): 36 had 23.4 Gy of CSI, and 8 had 30.6 Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4 Gy did not influence PFS. Female adult patients tended to have a better outcome than males. Conclusion: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.
- Published
- 2020
7. Contribution of common and rare genetic variants in CEP72 on vincristine-induced peripheral neuropathy in brain tumour patients
- Author
-
Klumpers, M.J., Brand, A.C.A.M., Hakobjan, M.H., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Gidding, C.E.M., Guchelaar, H.J., Loo, D.M.W.M. te, Coenen, M.J.H., Klumpers, M.J., Brand, A.C.A.M., Hakobjan, M.H., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Gidding, C.E.M., Guchelaar, H.J., Loo, D.M.W.M. te, and Coenen, M.J.H.
- Abstract
Item does not contain fulltext, AIMS: Studies implicated a role for a genetic variant in CEP72 in vincristine-induced peripheral neuropathy. This study aims to evaluate this association in a cohort of brain tumour patients, to perform a cross-disease meta-analysis and explore the protein-coding region of CEP72. METHODS: In total, 104 vincristine-treated brain tumour patients were genotyped for CEP72 rs924607, and sequenced for the protein-coding region. Data regarding patient and treatment characteristics, and peripheral neuropathy, were collected. Logistic regression and meta-analysis were performed for rs924607 replication. A weighted burden analysis was applied to evaluate impact of overall genetic variation in CEP72. RESULTS: Analysis of 24 cases and 80 controls did not show a significant association between CEP72 rs924607 and neuropathy (odds ratio, OR [95% confidence interval, CI] 2.076 [0.359-11.989], P = .414). When combined with 8 cohorts (1095 cancer patients), a significant increase in risk for neuropathy was found for patients with a TT genotype (OR [95% CI] 2.15 [1.35-3.43], P = .001). Additionally, a missense variant (rs12522955) was significantly associated (OR [95% CI] 2.3 [1.2-4.4], P = .041) and patients with severe neuropathy carried more impactful variants in CEP72 coding regions (P = .039). CONCLUSION: The association of CEP72 rs924607 in vincristine-induced neuropathy was not confirmed in a cohort of brain tumour patients, but did contribute to its suggested effect when combined in a cross-disease meta-analysis. The importance of other genetic variations in CEP72 on vincristine-induced neuropathy was demonstrated. This study contributes to evidence of the importance of genetic variants in CEP72 in development of vincristine-induced toxicity, and provides guidance for future prospective studies.
- Published
- 2022
8. Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort
- Author
-
Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, Terenziani, Monica, Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, and Terenziani, Monica
- Abstract
Background: Data on late mortality from pediatric germ cell tumors (GCTs) are limited to small case series. Our population-based study aimed to investigate excess risk of death in survivors of GCT in childhood and adolescence, whether long-term mortality changed over time and by period of diagnosis. Methods: The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 2773 five-year survivors diagnosed under 21 years of age with gonadal and extragonadal GCT (from 1940 to 2008). We calculated standardized mortality ratios (SMRs) and absolute excess risks (AERs). We fitted a Cox's model to assess the impact of treatment period. We estimated 10-year survival and calculated average percentage changes between periods of diagnosis (1970–1979, 1980–1989, 1990–1999) to assess whether late mortality decreased. Results: GCT survivors had an almost four-fold excess risk of dying compared to general population. The risk of death for patients treated after 1980 was nearly halved compared to patients treated before 1980. Survivors diagnosed in 1990–1999 had a 10-year survival rate of 99%, which was 2.4% and 1.1% higher than for patients treated in 1970–1979 and 1980–1989, respectively. Conclusions: This is the largest population-based study in Europe and showed a decrease in long-term mortality for survivors of GCTs in childhood and adolescence over the last decades. After the introduction of platinum compound in 1980, which is a paradigm of success compared to the previous treatments, no major changes in drug therapies have been made to treat GCTs in the last 40 years. However, GCT survivors maintain an excessive risk of death that requires long-term care.
- Published
- 2022
9. Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten
- Author
-
Quarello, P, Toss, A, Mascarin, M, Banna, G, Canesi, M, Milano, G, Incorvaia, L, Lambertini, M, Terenziani, M, Clerici, C, Vigevani, G, Beretta, G, Prete, A, Cinieri, S, Peccatori, F, Ferrari, A, Quarello, Paola, Toss, Angela, Mascarin, Maurizio, Banna, Giuseppe Luigi, Canesi, Marta, Milano, Giuseppe Maria, Incorvaia, Lorena, Lambertini, Matteo, Terenziani, Monica, Clerici, Carlo Alfredo, Vigevani, Giulio Enea, Beretta, Giordano Domenico, Prete, Arcangelo, Cinieri, Saverio, Peccatori, Fedro Alessandro, Ferrari, Andrea, Quarello, P, Toss, A, Mascarin, M, Banna, G, Canesi, M, Milano, G, Incorvaia, L, Lambertini, M, Terenziani, M, Clerici, C, Vigevani, G, Beretta, G, Prete, A, Cinieri, S, Peccatori, F, Ferrari, A, Quarello, Paola, Toss, Angela, Mascarin, Maurizio, Banna, Giuseppe Luigi, Canesi, Marta, Milano, Giuseppe Maria, Incorvaia, Lorena, Lambertini, Matteo, Terenziani, Monica, Clerici, Carlo Alfredo, Vigevani, Giulio Enea, Beretta, Giordano Domenico, Prete, Arcangelo, Cinieri, Saverio, Peccatori, Fedro Alessandro, and Ferrari, Andrea
- Abstract
Adolescent and young adult cancer survivors may experience various forms of social difficulties years or even decades after completing their cancer treatments. This article will hopefully help the Italian national project dedicated to adolescents and young adults with cancer promoting political and legal solutions to stop discrimination and supporting the right to be forgotten.
- Published
- 2022
10. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.
- Author
-
Hurkmans, EGE, Klumpers, MJ, Dello Russo, C, De Witte, W, Guchelaar, H-J, Gelderblom, H, Cleton-Jansen, A-M, Vermeulen, SH, Kaal, S, van der Graaf, WTA, Flucke, U, Gidding, CEM, Schreuder, HWB, de Bont, ESJM, Caron, HN, Gattuso, G, Schiavello, E, Terenziani, M, Massimino, M, McCowage, G, Nagabushan, S, Limaye, A, Rose, V, Catchpoole, D, Jorgensen, AL, Barton, C, Delaney, L, Hawcutt, DB, Pirmohamed, M, Pizer, B, Coenen, MJH, Te Loo, DMWM, Hurkmans, EGE, Klumpers, MJ, Dello Russo, C, De Witte, W, Guchelaar, H-J, Gelderblom, H, Cleton-Jansen, A-M, Vermeulen, SH, Kaal, S, van der Graaf, WTA, Flucke, U, Gidding, CEM, Schreuder, HWB, de Bont, ESJM, Caron, HN, Gattuso, G, Schiavello, E, Terenziani, M, Massimino, M, McCowage, G, Nagabushan, S, Limaye, A, Rose, V, Catchpoole, D, Jorgensen, AL, Barton, C, Delaney, L, Hawcutt, DB, Pirmohamed, M, Pizer, B, Coenen, MJH, and Te Loo, DMWM
- Abstract
Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value <10-5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5-2.7), p-value 5.0 × 10-7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.
- Published
- 2022
11. Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors
- Author
-
Perotti, D, Gamba, B, Sardella, M, Spreafico, F, Terenziani, M, Collini, P, Pession, A, Nantron, M, Fossati-Bellani, F, and Radice, P
- Published
- 2008
- Full Text
- View/download PDF
12. Transitory, spontaneously recovering, peripheral facial nerve palsy after vinorelbine administration
- Author
-
Massimino, M., Simonetti, F., Balestrini, M. R., Spreafico, F., La Spina, M., Terenziani, M., and Gandola, L.
- Published
- 2006
- Full Text
- View/download PDF
13. Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy
- Author
-
Ferrari, A, Zecca, M, Rizzari, C, Porta, F, Provenzi, M, Marinoni, M, Schumacher, R, Luksch, R, Terenziani, M, Casanova, M, Spreafico, F, Chiaravalli, S, Compagno, F, Bruni, F, Piccolo, C, Bettini, L, D'Angiò, M, Ferrari, G, Biondi, A, Massimino, M, Balduzzi, A, Ferrari, Andrea, Zecca, Marco, Rizzari, Carmelo, Porta, Fulvio, Provenzi, Massimo, Marinoni, Maddalena, Schumacher, Richard Fabian, Luksch, Roberto, Terenziani, Monica, Casanova, Michela, Spreafico, Filippo, Chiaravalli, Stefano, Compagno, Francesca, Bruni, Federica, Piccolo, Chiara, Bettini, Laura, D'Angiò, Mariella, Ferrari, Giulia Maria, Biondi, Andrea, Massimino, Maura, Balduzzi, Adriana, Ferrari, A, Zecca, M, Rizzari, C, Porta, F, Provenzi, M, Marinoni, M, Schumacher, R, Luksch, R, Terenziani, M, Casanova, M, Spreafico, F, Chiaravalli, S, Compagno, F, Bruni, F, Piccolo, C, Bettini, L, D'Angiò, M, Ferrari, G, Biondi, A, Massimino, M, Balduzzi, A, Ferrari, Andrea, Zecca, Marco, Rizzari, Carmelo, Porta, Fulvio, Provenzi, Massimo, Marinoni, Maddalena, Schumacher, Richard Fabian, Luksch, Roberto, Terenziani, Monica, Casanova, Michela, Spreafico, Filippo, Chiaravalli, Stefano, Compagno, Francesca, Bruni, Federica, Piccolo, Chiara, Bettini, Laura, D'Angiò, Mariella, Ferrari, Giulia Maria, Biondi, Andrea, Massimino, Maura, and Balduzzi, Adriana
- Published
- 2020
14. Investigating sexuality in adolescents with cancer: patients talk of their experiences
- Author
-
Veneroni, L, Pagani Bagliacca, E, Sironi, G, Silva, M, Casanova, M, Bergamaschi, L, Terenziani, M, Trombatore, J, Prunas, A, Silvaggi, M, Massimino, M, Ferrari, A, Veneroni, L, Pagani Bagliacca, E, Sironi, G, Silva, M, Casanova, M, Bergamaschi, L, Terenziani, M, Trombatore, J, Prunas, A, Silvaggi, M, Massimino, M, and Ferrari, A
- Abstract
Objective. The aim of the present study is to understand which areas of sexuality were regarded as most important and/or problematic among adolescents with cancer. Methods. A questionnaire was administered to adolescent and young adult patients who had been receiving treatments at the Pediatric Oncology Unit of our Institution, for at least 2 months, and those in follow-up who had completed their treatments no more than two years previously. The questionnaire was devised to investigate patients’ experiences in various areas, i.e. personal relations, sexual relations; functional aspects, body image, and communication. Results. Questionnaires were given to 70 patients and completed by 66. As main results, the survey showed that disease and treatment might negatively affect patients’ way of relating with others (53% of cases) and their body image (56%), though their sexual desire remains unchanged (69.7%). Most patients (67%) reported not having the chance to talk to someone about having sex while receiving their treatments; 79% of patients felt this topic deserved more attention. Conclusion. This study promotes the discussion of an important topic for young people with cancer, which is inadequately addressed today. When establishing an age-specific model of care, aspects related to sexuality should be considered and managed.
- Published
- 2020
15. Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients
- Author
-
Zambetti, M., Demicheli, R., Candis, D. De, Antonelli, G., Giacobone, A., Terenziani, M., Laffranchi, A., Garbagnati, F., Biasi, S., and Bonadonna, G.
- Published
- 1997
- Full Text
- View/download PDF
16. 090 - TREATING LYMPHOMA IN THE PANDEMIC ERA: WHAT WE LEARNED FROM OUR EXPERIENCE AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
- Author
-
Gattuso, G., Biassoni, V., Podda, M., Meazza, C., Chiaravalli, S., Nigro, O., Sironi, G., Livellara, V., Puma, N., Bergamaschi, L., Terenziani, M., Spreafico, F., Massimino, M., and Schiavello, E.
- Published
- 2022
- Full Text
- View/download PDF
17. BREAST CANCER SCREENING PROGRAM FOR PEDIATRIC CANCER SURVIVORS, PREVIOUSLY TREATED WITH RADIOTHERAPY ON CHEST WALL: P.L.045
- Author
-
Terenziani, M., Lepera, Paolo, Bergonzi, Silvana, Gandola, Lorenza, Tagliabue, Elda, Meazza, Cristina, Podda, Marta, Spreafico, Filippo, Collini, Paola, Clerici, Carlo Alfredo, Gennaro, Massimiliano, Massimino, Maura, Cefalo, Graziella, Casanova, Michela, Ferrari, Andrea, Polastri, Daniela, Luksch, Roberto, Fagnani, Anna Maria, and Fossati-Bellani, Franca
- Published
- 2005
18. Late excess mortality in survivors of childhood and adolescent cancer: Results from the PanCareSurFup Study
- Author
-
Schmidtmann, I, Byrne, J, Rashid, H, Grabow, D, Hagberg, O, Bardi, E, De Vathaire, F, Falck Winther, J, Gudmundsdottir, T, Haupt, R, Hawkins, MM, Jakab, Z, Jankovic, M, Kaatsch, P, Kremer, LMC, Kuehni, CE, Lähteenmäki, PM, Ronckers, CM, Sacerdote, C, Skinner, R, Terenziani, M, Zadravec Zaletel, L, Hjorth, L, Schmidtmann, I, Byrne, J, Rashid, H, Grabow, D, Hagberg, O, Bardi, E, De Vathaire, F, Falck Winther, J, Gudmundsdottir, T, Haupt, R, Hawkins, MM, Jakab, Z, Jankovic, M, Kaatsch, P, Kremer, LMC, Kuehni, CE, Lähteenmäki, PM, Ronckers, CM, Sacerdote, C, Skinner, R, Terenziani, M, Zadravec Zaletel, L, and Hjorth, L
- Published
- 2019
19. Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960–1999 and registered in the Italian Off-Therapy Registry
- Author
-
Bagnasco, F., Caruso, S., Andreano, A., Valsecchi, M. G., Jankovic, M., Biondi, A., Miligi, L., Casella, C., Terenziani, M., Massimino, M., Sacerdote, C., Morsellino, V., Erminio, G., Garaventa, A., Faraci, M., Micalizzi, C., Garre, M. L., Pillon, M., Basso, G., Biasin, E., Fagioli, F., Rondelli, R., Pession, A., Locatelli, Franco, Santoro, N., Indolfi, P., Palumbo, G., Russo, G., Verzegnassi, F., Favre, C., Zecca, M., Mura, R., D'Angelo, P., Cano, C., Byrne, J., Haupt, R., Pierani, P., Porta, F., Consarino, C., Burnelli, R., Fedeli, F., Cellini, M., Casale, F., Menna, G., Bertolini, P., Caniglia, M., Cecinati, V., Casazza, G., Foa, R., Clerico, A., Ladogana, S., Galimberti, D., Rabusin, M., Nespoli, L., Cesaro, S., Locatelli F. (ORCID:0000-0002-7976-3654), Bagnasco, F., Caruso, S., Andreano, A., Valsecchi, M. G., Jankovic, M., Biondi, A., Miligi, L., Casella, C., Terenziani, M., Massimino, M., Sacerdote, C., Morsellino, V., Erminio, G., Garaventa, A., Faraci, M., Micalizzi, C., Garre, M. L., Pillon, M., Basso, G., Biasin, E., Fagioli, F., Rondelli, R., Pession, A., Locatelli, Franco, Santoro, N., Indolfi, P., Palumbo, G., Russo, G., Verzegnassi, F., Favre, C., Zecca, M., Mura, R., D'Angelo, P., Cano, C., Byrne, J., Haupt, R., Pierani, P., Porta, F., Consarino, C., Burnelli, R., Fedeli, F., Cellini, M., Casale, F., Menna, G., Bertolini, P., Caniglia, M., Cecinati, V., Casazza, G., Foa, R., Clerico, A., Ladogana, S., Galimberti, D., Rabusin, M., Nespoli, L., Cesaro, S., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Introduction: Advances in paediatric oncology led to the increase in long-term survival, revealing the burden of therapy-related long-term side effects. We evaluated overall and cause-specific mortality in a large cohort of Italian childhood cancer survivors (CCSs) and adolescent cancer survivors identified through the off-therapy registry. Materials and methods: CCSs alive 5 years after cancer diagnosis occurring between 1960 and 1999 were eligible; the last follow-up was between 2011 and 2014. Outcomes were reported as standardised mortality ratios (SMRs) and absolute excess risks (AERs). Results: Among 12,214 CCSs, 1113 (9.1%) deaths occurred. Survival at 35 years since diagnosis was 87% (95% confidence interval [CI]: 86–88) and at 45 years was 81% (95% CI: 77–84). CCSs had an 11-fold increased risk of death (SMR 95% CI: 10.7–12), corresponding to an AER of 48 (95% CI: 45–51). Mortality decreased by 60% for survivors treated most recently (1990–1999). The most frequent causes of death were recurrence of the original cancer (56%), a subsequent neoplasm (19%) and cardiovascular diseases (5.8%). Among those who survived at least 15 years after diagnosis, a secondary malignancy was the leading cause of death. Conclusions: This study confirms the impact of recent advances in anticancer therapy in reducing mortality, mainly attributable to recurrence but also to other causes. However, overall mortality continues to be higher than in the general population. A long-term follow-up is needed to prevent late mortality due to secondary neoplasms and non-neoplastic causes in CCSs.
- Published
- 2019
20. Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960–1999 and registered in the Italian Off-Therapy Registry
- Author
-
Bagnasco, F, Caruso, S, Andreano, A, Valsecchi, M, Jankovic, M, Biondi, A, Miligi, L, Casella, C, Terenziani, M, Massimino, M, Sacerdote, C, Morsellino, V, Erminio, G, Garaventa, A, Faraci, M, Micalizzi, C, Garrè, M, Pillon, M, Basso, G, Biasin, E, Fagioli, F, Rondelli, R, Pession, A, Locatelli, F, Santoro, N, Indolfi, P, Palumbo, G, Russo, G, Verzegnassi, F, Favre, C, Zecca, M, Mura, R, D'Angelo, P, Cano, C, Byrne, J, Haupt, R, Pierani, P, Porta, F, Consarino, C, Burnelli, R, Fedeli, F, Cellini, M, Casale, F, Menna, G, Bertolini, P, Caniglia, M, Cecinati, V, Casazza, G, Foà, R, Clerico, A, Ladogana, S, Galimberti, D, Rabusin, M, Nespoli, L, Cesaro, S, Bagnasco, Francesca, Caruso, Silvia, Andreano, Anita, Valsecchi, Maria Grazia, Jankovic, Momcilo, Biondi, Andrea, Miligi, Lucia, Casella, Claudia, Terenziani, Monica, Massimino, Maura, Sacerdote, Carlotta, Morsellino, Vera, Erminio, Giovanni, Garaventa, Alberto, Faraci, Maura, Micalizzi, Concetta, Garrè, Maria Luisa, Pillon, Marta, Basso, Giuseppe, Biasin, Eleonora, Fagioli, Franca, Rondelli, Roberto, Pession, Andrea, Locatelli, Franco, Santoro, Nicola, Indolfi, Paolo, Palumbo, Giovanna, Russo, Giovanna, Verzegnassi, Federico, Favre, Claudio, Zecca, Marco, Mura, Rossella, D'Angelo, Paolo, Cano, Carmen, Byrne, Julianne, Haupt, Riccardo, Pierani, Paolo, Pession, Andreea, Porta, Fulvio, Consarino, Caterina, Burnelli, Roberta, Fedeli, Fausto, Cellini, Monica, Casale, Fiorina, Menna, Giuseppe, Bertolini, Patrizia, Caniglia, Maurizio, Cecinati, Valerio, Casazza, Gabriella, Foà, Roberto, Clerico, Anna, Ladogana, Saverio, Galimberti, Daniela, Rabusin, Marco, Nespoli, Luigi, Cesaro, Simone, Bagnasco, F, Caruso, S, Andreano, A, Valsecchi, M, Jankovic, M, Biondi, A, Miligi, L, Casella, C, Terenziani, M, Massimino, M, Sacerdote, C, Morsellino, V, Erminio, G, Garaventa, A, Faraci, M, Micalizzi, C, Garrè, M, Pillon, M, Basso, G, Biasin, E, Fagioli, F, Rondelli, R, Pession, A, Locatelli, F, Santoro, N, Indolfi, P, Palumbo, G, Russo, G, Verzegnassi, F, Favre, C, Zecca, M, Mura, R, D'Angelo, P, Cano, C, Byrne, J, Haupt, R, Pierani, P, Porta, F, Consarino, C, Burnelli, R, Fedeli, F, Cellini, M, Casale, F, Menna, G, Bertolini, P, Caniglia, M, Cecinati, V, Casazza, G, Foà, R, Clerico, A, Ladogana, S, Galimberti, D, Rabusin, M, Nespoli, L, Cesaro, S, Bagnasco, Francesca, Caruso, Silvia, Andreano, Anita, Valsecchi, Maria Grazia, Jankovic, Momcilo, Biondi, Andrea, Miligi, Lucia, Casella, Claudia, Terenziani, Monica, Massimino, Maura, Sacerdote, Carlotta, Morsellino, Vera, Erminio, Giovanni, Garaventa, Alberto, Faraci, Maura, Micalizzi, Concetta, Garrè, Maria Luisa, Pillon, Marta, Basso, Giuseppe, Biasin, Eleonora, Fagioli, Franca, Rondelli, Roberto, Pession, Andrea, Locatelli, Franco, Santoro, Nicola, Indolfi, Paolo, Palumbo, Giovanna, Russo, Giovanna, Verzegnassi, Federico, Favre, Claudio, Zecca, Marco, Mura, Rossella, D'Angelo, Paolo, Cano, Carmen, Byrne, Julianne, Haupt, Riccardo, Pierani, Paolo, Pession, Andreea, Porta, Fulvio, Consarino, Caterina, Burnelli, Roberta, Fedeli, Fausto, Cellini, Monica, Casale, Fiorina, Menna, Giuseppe, Bertolini, Patrizia, Caniglia, Maurizio, Cecinati, Valerio, Casazza, Gabriella, Foà, Roberto, Clerico, Anna, Ladogana, Saverio, Galimberti, Daniela, Rabusin, Marco, Nespoli, Luigi, and Cesaro, Simone
- Abstract
Introduction: Advances in paediatric oncology led to the increase in long-term survival, revealing the burden of therapy-related long-term side effects. We evaluated overall and cause-specific mortality in a large cohort of Italian childhood cancer survivors (CCSs) and adolescent cancer survivors identified through the off-therapy registry. Materials and methods: CCSs alive 5 years after cancer diagnosis occurring between 1960 and 1999 were eligible; the last follow-up was between 2011 and 2014. Outcomes were reported as standardised mortality ratios (SMRs) and absolute excess risks (AERs). Results: Among 12,214 CCSs, 1113 (9.1%) deaths occurred. Survival at 35 years since diagnosis was 87% (95% confidence interval [CI]: 86–88) and at 45 years was 81% (95% CI: 77–84). CCSs had an 11-fold increased risk of death (SMR 95% CI: 10.7–12), corresponding to an AER of 48 (95% CI: 45–51). Mortality decreased by 60% for survivors treated most recently (1990–1999). The most frequent causes of death were recurrence of the original cancer (56%), a subsequent neoplasm (19%) and cardiovascular diseases (5.8%). Among those who survived at least 15 years after diagnosis, a secondary malignancy was the leading cause of death. Conclusions: This study confirms the impact of recent advances in anticancer therapy in reducing mortality, mainly attributable to recurrence but also to other causes. However, overall mortality continues to be higher than in the general population. A long-term follow-up is needed to prevent late mortality due to secondary neoplasms and non-neoplastic causes in CCSs.
- Published
- 2019
21. PEDIATRIC TESTICULAR GERM CELL TUMORS: the ASSOCIAZIONE ITALIANA ONCOLOGIA PEDIATRICA (AIEOP) study
- Author
-
TERENZIANI,M, CONTE,M, BIASONI,D, BOLDRINI,R, COLLINI,P, PINTO,D, SPREAFICO,F, BISOGNO,G, DE PASQUALE,M, CECCHETTO,G, INSERRA,A, D'ANGELO,P, SIRACUSA, Fortunato, TERENZIANI,M, CONTE,M, BIASONI,D, BOLDRINI,R, COLLINI,P, PINTO,D, SPREAFICO,F, BISOGNO,G, DE PASQUALE,M, CECCHETTO,G, INSERRA,A, D'ANGELO,P, and SIRACUSA,F.
- Subjects
Testicular Germ Cell Tumors in childood, chemotherapy, pediatric surgery - Abstract
We describe the results of a therapeutic approach with a pediatric BEP regimen (bleomycin, etoposide, cisplatin) from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) study on testicular germ cell tumors (TGCT).
- Published
- 2017
22. Undifferentiated nasopharyngeal carcinoma in children and adolescents: Comparison between staging systems
- Author
-
Casanova, M., Ferrari, A., Gandola, L., Orlandi, E., Spreafico, F., Terenziani, M., Navarria, P., Luksch, R., Massimino, M., Cefalo, G., Lombardi, F., and Fossati-Bellani, F.
- Published
- 2001
23. Loss of Heterozygosity Analysis at Different Chromosome Regions in Wilms Tumor Confirms 1p Allelic Loss as a Marker of Worse Prognosis: A Study from the Italian Association of Pediatric Hematology and Oncology
- Author
-
Spreafico F, Gamba B, Mariani L, Collini P, D'Angelo P, Di Cataldo A, Indolfi P, Nantron M, Terenziani M, Morosi C, Radice P, Perotti D, AIEOP Wilms Tumor Working Group, PESSION, ANDREA, Spreafico F, Gamba B, Mariani L, Collini P, D'Angelo P, Pession A, Di Cataldo A, Indolfi P, Nantron M, Terenziani M, Morosi C, Radice P, Perotti D, and AIEOP Wilms Tumor Working Group
- Subjects
Genetic Markers ,Male ,Oncology ,medicine.medical_specialty ,Vincristine ,Multivariate analysis ,Adolescent ,pediatrics ,kidney neoplasms, loss of heterozygosity, pediatrics, Wilms tumor ,Urology ,STAGE-I, CHILDRENS-CANCER, RENAL TUMORS, SHORT ARM, 16Q, ANAPLASIA, RELAPSE, GENE, 11Q, AGE ,Loss of heterozygosity ,Chromosome regions ,Internal medicine ,medicine ,Overall survival ,Humans ,kidney neoplasms ,Prospective Studies ,Child ,loss of heterozygosity ,Wilms tumor ,business.industry ,Infant ,Wilms' tumor ,Prognosis ,medicine.disease ,Child, Preschool ,Microsatellite ,Female ,business ,Allelic loss ,medicine.drug - Abstract
PURPOSE: The specific aims of the AIEOP-TW-2003 protocol included prospectively investigating a possible association of tumor loss of heterozygosity with outcomes in children treated for Wilms tumor. MATERIALS AND METHODS: We analyzed 125 unilateral favorable histology Wilms tumors registered between 2003 and 2008 in the Italian cooperative protocol for microsatellite markers mapped to chromosomes 1p, 7p, 11q, 16q and 22q. RESULTS: The 3-year disease-free survival and overall survival probabilities were 0.87 (95% CI 0.81-0.93) and 0.98 (95% CI 0.96-1.0), respectively. Loss of heterozygosity at 1p was significantly associated with a worse disease-free survival (probability 0.67 for patients with and 0.92 for those without 1p loss of heterozygosity, p = 0.0009), as confirmed also by multivariate analysis adjusting for tumor stage and patient age at diagnosis. There was no difference in disease-free survival probability among children with loss of heterozygosity in the other chromosomal regions tested. The worse outlook for children older than 2 years at diagnosis did not seem to be influenced by the loss of heterozygosity patterns considered. CONCLUSIONS: Chromosome 1p loss of heterozygosity seems to be a risk factor for nonanaplastic Wilms tumor, possibly regardless of other clinical factors. Our findings were uninformative regarding loss of heterozygosity in the other chromosomal regions tested.
- Published
- 2013
24. Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)
- Author
-
Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, Hjorth, Lars, Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, and Hjorth, Lars
- Abstract
Purpose: The number of persons who have successfully completed treatment for a cancer diagnosed during childhood and who have entered adulthood is increasing over time, and former patients will become aging citizens. Methods: Ten years ago, an expert panel met in Erice, Italy, to produce a set of principles concerning the cure and care of survivors of childhood and adolescent cancer. The result was the Erice Statement (Haupt et al. Eur J Cancer 43(12):1778–80, 2007) that was translated into nine languages. Ten years on, it was timely to review, and possibly revise, the Erice Statement in view of the changes in paediatric oncology and the number and results of international follow-up studies conducted during the intervening years. Results: The long-term goal of the cure and care of a child with cancer is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, accepted in society at the same level as his/her age peers. “Cure” refers to cure from the original cancer, regardless of any potential for, or presence of, remaining disabilities or side effects of treatment. The care of a child with cancer should include complete and honest information for parents and the child. Conclusions and implication for cancer survivors: Some members of the previous expert panel, as well as new invited experts, met again in Erice to review the Erice Statement, producing a revised version including update and integration of each of the ten points. In addition, a declaration has been prepared, by the Childhood Cancer International Survivors Network in Dublin on October 2016 (see Annex 1).
- Published
- 2018
25. Mature and immature teratoma: A report from the second Italian pediatric study
- Author
-
Terenziani, M., D'Angelo, P., Inserra, A., Boldrini, R., Bisogno, G., Babbo, G., Conte, M., Dall' Igna, P., De Pasquale, M., Indolfi, P., Piva, L., Riccipetitoni, G., Siracusa, F., Spreafico, L., Tamaro, P., Cecchetto, G., Terenziani, M, D'Angelo, P, Inserra, A, Boldrini, R, Bisogno, G, Babbo, GL, Conte, M, Dall' Igna, P, De Pasquale, MD, Indolfi, P, Piva, L, Riccipetitoni,G, Siracusa, F, Spreafico, L, Tamaro, P, and Cecchetto, G
- Subjects
immature teratoma ,Settore MED/20 - Chirurgia Pediatrica E Infantile ,Settore MED/20 ,germ cell tumor ,mature teratoma ,germ cell tumors ,childhood - Abstract
Background. Teratomas demonstrate a benign clinical behavior, however they may recur with malignant components or as teratoma, and in a small group of patients prognosis could be fatal. After the ®rst Italian study, we collected cases of teratoma, alongside the protocol for malignant germ cell tumors. Procedure. Patients with teratoma were collected from 2004 to 2014. Teratomas were classi®ed according to the WHO classi®cations, as mature and immature. Patients with pathological aFP and/or bHCG, and those with a malignant germ cell component were not included. Results. The study enrolled 219 patients (150 mature, 69 immature teratomas) with a median age at diagnosis of 42 months. The primary sites involved were: 118 gonadal and 101 extragonadal teratomas. Two females with ovarian teratoma had a positive family history. Complete and incomplete surgeries were performed in 85% and 9% of cases. Seventeen events occurred: six females had a second metachronous tumor (5 contralateral ovarian teratoma, 1 adrenal neuroblastoma) and 11 teratomas relapsed/progressed (3 mature, 8 immature teratomas). Two patients died, one of progressive immature teratoma and one of surgical complications. At a median follow up of 68 months, the event-free, relapse-free, and overall survival rates were 90.6%, 94.3%, 98.6%, respectively. Conclusions. Teratomas show a good prognosis, especially the mature ones: surgery and follow-up remain the standard approach. Incomplete surgery in immature teratoma is the group at greatest risk of relapse. Bilateral ovarian tumors are a possibility, and the rare family predisposition to ovarian mature teratoma warrants further analyses.
- Published
- 2015
26. Combined sequential approach in locally advanced breast cancer
- Author
-
Zambetti, M., Oriana, S., Quattrone, P., Verderio, P., Terenziani, M., Zucali, R., Valagussa, P., and Bonadonna, G.
- Published
- 1999
- Full Text
- View/download PDF
27. Marriage and parenthood among subjects cured of childhood cancer: a report from the Italian AIEOP Off-Therapy Registry
- Author
-
Pivetta, EMANUELE EMILIO, Maule, MILENA MARIA, Pisani, Paola, Zugna, Daniela, Haupt, R, Jankovic, M, Arico', M, Casale, F, Clerico, A, CORDERO DI MONTEZEMOLO, Luca, Kiren, V, Locatelli, F, Palumbo, G, Pession, A, Pillon, M, Santoro, N, Terenziani, M, Valsecchi, Mg, Dama, Elisa, Magnani, C, Merletti, Franco, Pastore, G., Pivetta E., Maule MM., Pisani P., Zugna D., Haupt R., Jankovic M., Arico' M., Casale F., Clerico A., Cordero di Montezemolo L., Kiren V., Locatelli F., Palumbo G., Pession A., Pillon M., Santoro N., Terenziani M., Valsecchi MG., Dama E., Magnani C., Merletti F., Pastore G., Pivetta, E, Maule, Mm, Pisani, P, Zugna, D, Haupt, R, Jankovic, M, Aricò, M, Casale, Fiorina, Clerico, A, CORDERO DI MONTEZEMOLO, L, Kiren, V, Locatelli, F, Palumbo, G, Pession, A, Pillon, M, Santoro, N, Terenziani, M, Valsecchi, Mg, Dama, E, Magnani, C, Merletti, F, and Pastore, G.
- Subjects
Quality of life ,Fertility ,childhood cancer ,Marriage ,Long-term survivors ,childhood cancer, marriage, fertility, long-term survivors, quality of life - Abstract
The aim of this study was to describe the patterns of marriage and parenthood in a cohort of childhood cancer survivors included in the Off-Therapy Registry maintained by the Italian Association of Pediatric Hematology and Oncology. Design and Methods We analyzed a cohort of 6,044 patients diagnosed with cancer between 1960 and 1998, while aged 0 to 14 years and who were 18 years old or older by December 2003. They were followed up through the regional vital statistics registers until death or the end of follow up (October 30, 2006), whichever occurred first, and their marital status and date of birth of their children were recorded. The cumulative probabilities of being married and having a first child were computed by gender and compared by tumor type within the cohort. Marriage and fertility rates (the latter defined as the number of live births per woman-year) were compared with those of the Italian population of the same age, gender, area of residence and calendar period by means of the observed to expected (O/E) ratios. Results During the follow-up period, 4,633 (77%) subjects had not married. The marriage O/E ratios were 0.56 (95% CI: 0.51-0.61) and 0.70 (95% CI: 0.65-0.76) among men and women, respectively. Overall, 263 men had 367 liveborn children, and 473 women had 697 liveborn children. The female fertility O/E ratio was 0.57 (95% CI: 0.53-0.62) overall, and 1.08 (95% CI: 0.99-1.17) when analyses were restricted to married/cohabiting women Conclusions Childhood cancer survivors are less likely to marry and to have children than the general population, confirming the life-long impact of their previous disease on their social behavior and choices. The inclusion of counseling in the strategies of management and long-term surveillance of childhood cancer patients could be beneficial to survivors as they approach adulthood.
- Published
- 2011
28. Mediastinal Germ Cell Tumors in Pediatric Patients: A Report From the Italian Association of Pediatric Hematology and Oncology
- Author
-
De Pasquale, Md, Crocoli, A, Conte, M, Indolfi, P, D'Angelo, P, Boldrini, R, Terenziani, M, and Inserra, A
- Subjects
Settore MED/20 - Published
- 2016
29. Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study
- Author
-
Terenziani, M., primary, Bisogno, G., additional, Boldrini, R., additional, Cecchetto, G., additional, Conte, M., additional, Boschetti, L., additional, De Pasquale, M.D., additional, Biasoni, D., additional, Inserra, A., additional, Siracusa, F., additional, Basso, M.E., additional, De Leonardis, F., additional, Di Pinto, D., additional, Barretta, F., additional, Spreafico, F., additional, and D'Angelo, P., additional
- Published
- 2017
- Full Text
- View/download PDF
30. cured&rdquo
- Author
-
Tralongo, P., Maso, L. Dal, Surbone, A., Santoro, A., Tirelli, U., Sacchini, V., Pinto, C., Crispino, S., Ferraù, F., Mandoliti, G., Tonini, G., Russo, A., Santini, D., Madeddu, A., Panebianco, V., Pergolizzi, S., Respini, D., Rolfo, C., Bongiovanni, M., Lorenzo, F. De, Spatola, C., Raimondo, F. Di, Terenziani, M., Peeters, M., and Castoro, C.
- Subjects
Long-term survival ,cure ,implications - Abstract
Long-term survival for adult patients with solid tumours continues to increase. For some cancers, the possibility of recurrence after a number of years is extremely low, and the risk of death becomes similar to that of the general population of the same sex and age.
- Published
- 2015
- Full Text
- View/download PDF
31. STAGE-I GOMADAL GERMS CELL TUMORS (GGCT):OUTCOME AFTER THE SURVEILLANCE STRATEGY AS APPLIED IN THE ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA (AIEOP) 2004 PROTOCOL
- Author
-
Terenziani,M, D'Angelo,P, Bisogno,G, Cecchetto,G, Inserra,A, SIRACUSA, Fortunato, Terenziani,M, Siracusa,F, D'Angelo,P, Bisogno,G, Cecchetto,G, and Inserra,A
- Subjects
Settore MED/20 - Chirurgia Pediatrica E Infantile ,PAEDIATRIC TUMORS, GERMS CELL TUMORS - Published
- 2012
32. STAGE I GONADAL CELL TUMORS (GGCT): OUTCOME AFETR THE SURVEILLANCE STRATEGY AS APPLIED IN THE ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA (aieop) 2004 PROTOCOL
- Author
-
Terenziani, M., D'Angelo, P., Bisogno, G., Siracusa, F., Boldrini, R., Cecchetto, G., Collini, P., Conte, M., De Pasquale, M., Indolfi, P., Inserra, A., Piva, L., Spreafico, F., Terenziani, M., D'Angelo, P., Bisogno, G., Siracusa, F., Boldrini, R., Cecchetto, G., Collini, P., Conte, M., De Pasquale, M., Indolfi, P., Inserra, A., Piva, L., and Spreafico, F.
- Subjects
Settore MED/38 - Pediatria Generale E Specialistica ,Settore MED/20 - Chirurgia Pediatrica E Infantile ,germ cell tumors, stage 1° - Abstract
Suveillance strategy is a standerd option in stage 1° testicular GCT and suggested for ovarian GCT too. Worries regarding the relapse risk in ovarian are emerging. We here report on our series of stage 1° GGCT
- Published
- 2012
33. SURGERY IN PATIENTS WITH TESTICULAR MALIGNANT GERM CELL TUMORS: COMPLIANCE TO SURGICAL GUIDELINES AND RESULTS IN THE ITALIAN COOPERATIVE STUDY
- Author
-
Cecchetto, G., Siracusa, F., Piva, L., Inserra, A., Boschetti, L., D'Angelo, P., Terenziani, M., Cecchetto, G, Siracusa, F, Piva, L, Inserra, A, Boschetti, L, D'Angelo, P, and Terenziani, M
- Subjects
Settore MED/20 - Chirurgia Pediatrica E Infantile ,Testicular Tumors in Childhood, Germ Cells Tumours - Abstract
Purpose: Surgery represents a main and often the only treatment in patients with testicular Malignant Germ Cell Tumors (MGCT). We analyzed the compliance to surgical guidelines and the results in a series of patients with testicular MGCT -/+ retroperitoneal node involvement, without distant metastases. Method: 42 patients, observed in 15 Centers were enrolled in the Italian Cooperative Study on MGCT (January2004–December2010). 14/42 were younger than 2 y. of age, 28/42 between 13–18 y. Treatment was delivered according to COG-Staging-System: St.I patients (complete excision with inguinal orchifunicolectomy+decrease of markers, +hemiscrotectomy if scrotal involvement) did not receive further treatment; St.II patients (scrotal involvement after hemiscrotectomy and/or retroperitoneal node (RPN) enlargement:2 cm) had RPN Dissection if residuals were suspected after PEBx3or4. Results: St.I: 26 patients. 3/26 had a scrotal approach due to suspected testicular torsion: 1/3 underwent hemiscrotectomy, 2 did not receive further therapy after decrease of alphaFP, due to patient’s or physician’s decision respectively. 3/26 were successfully treated for RPN relapse, occurred at 3,6,9 months after adequate surgery (2 adolescents, 1 infant). St.II: in 4 patients CTwas delivered due to slight enlargement of RPN (+persistent alphaFP in 1). St.III: 12 patients received CT and RPND (bilateral in 1). Histology was negative in 11/12. All patients are alive without disease, 39 in 1stCR, 3 in 2ndCR (f.u 9–86 m.:med.48). 1 St.1 patient suffered from postoperative scrotal hematoma. Among patients younger than 2 y, 10/14 had a pure YST, 12/14 had St.I disease; among those between 13–18 y, 27/28 had a mixed histology, 14/28 were St.II or St.III. In 3 adolescents a testicular prosthesis was positioned during primary operation. Conclusion: Outcome was excellent. Regional relapses, observed only in St.I patients, were cured. Surgical guidelines were followed in 40/42 cases. Scrotal approach did not worsen the outcome of patients who did not receive further treatment.
- Published
- 2011
34. Marriage and parenthood among childhood cancer survivors: a report from the Italian AIEOP Off-Therapy Registry
- Author
-
Pivetta, E, Maule, Mm, Pisani, P, Zugna, D, Haupt, R, Jankovic, M, Aricò, M, Casale, F, Clerico, A, Cordero di Montezemolo, L, Kiren, V, Locatelli, F, Palumbo, G, Pession, A, Pillon, M, Santoro, N, Terenziani, M, Valsecchi, Mg, Dama, E, Magnani, C, Merletti, F, Pastore, G, Fagioli, F, Bona, G, Dini, G, Carnelli, V, Biondi, A, Zecca, M, Conter, V, Porta, F, Fedeli, F, Massimino, M, Nespoli, L, Roncarolo, Mg, Carli, M, Cesaro, S, Memo, L, Colleselli, P, Battisti, L, Tamaro, Paolo, Mascarin, M, Nocerino, A, Izzi, G, Paolucci, P, Borgna, Pc, Vecchi, V, Abate, Me, Acquaviva, A, Favre, C, Aversa, F, Pierani, P, Felici, L, Visani, G, Fioritoni, G, Foa, R, Riccardi, R, Frega, G, Poggi, V, Amendola, G, Filosa, A, Ladogana, S, Presta, G, Pozzi, S, De Mattia, D, Consarino, C, Nobile, F, Sperlì, D, D'Angelo, P, Marino, S, Gallisai, D, Targhetta, R., Pivetta, E, Maule, M, Pisani, P, Zugna, D, Haupt, R, Jankovic, M, Aricò, M, Casale, F, Clerico, A, Cordero di Montezemolo, L, Kiren, V, Locatelli, F, Palumbo, G, Pession, A, Pillon, M, Santoro, N, Terenziani, M, Valsecchi, M, Dama, E, Magnani, C, Merletti, F, Pastore, G, Maule, Mm, Valsecchi, Mg, Fagioli, F, Bona, G, Dini, G, Carnelli, V, Biondi, A, Zecca, M, Conter, V, Porta, F, Fedeli, F, Massimino, M, Nespoli, L, Roncarolo, Mg, Carli, M, Cesaro, S, Memo, L, Colleselli, P, Battisti, L, Tamaro, Paolo, Mascarin, M, Nocerino, A, Izzi, G, Paolucci, P, Borgna, Pc, Vecchi, V, Abate, Me, Acquaviva, A, Favre, C, Aversa, F, Pierani, P, Felici, L, Visani, G, Fioritoni, G, Foa, R, Riccardi, R, Frega, G, Poggi, V, Amendola, G, Filosa, A, Ladogana, S, Presta, G, Pozzi, S, De Mattia, D, Consarino, C, Nobile, F, Sperlì, D, D'Angelo, P, Marino, S, Gallisai, D, and Targhetta, R.
- Subjects
Adult ,Male ,Parents ,Pediatrics ,medicine.medical_specialty ,Total fertility rate ,media_common.quotation_subject ,Population ,Editorials and Perspectives ,Fertility ,off-therapy ,cancer survival ,Cohort Studies ,Quality of life ,Marriage and parenthood ,Medicine ,Humans ,cancer ,cancer survivors ,childhood ,Registries ,Survivors ,Marriage ,education ,Child ,media_common ,education.field_of_study ,business.industry ,Infant, Newborn ,Infant ,Hematology ,Original Articles ,Middle Aged ,childhood cancer ,fertility ,long-term survivors ,marriage ,quality of life ,El Niño ,Italy ,Child, Preschool ,Hematologic Neoplasms ,Cohort ,Marital status ,Female ,business ,Cohort study ,Follow-Up Studies - Abstract
Background The aim of this study was to describe the patterns of marriage and parenthood in a cohort of childhood cancer survivors included in the Off-Therapy Registry maintained by the Italian Association of Pediatric Hematology and Oncology. Design and Methods We analyzed a cohort of 6,044 patients diagnosed with cancer between 1960 and 1998, while aged 0 to 14 years and who were 18 years old or older by December 2003. They were followed up through the regional vital statistics registers until death or the end of follow up (October 30, 2006), whichever occurred first, and their marital status and date of birth of their children were recorded. The cumulative probabilities of being married and having a first child were computed by gender and compared by tumor type within the cohort. Marriage and fertility rates (the latter defined as the number of live births per woman-year) were compared with those of the Italian population of the same age, gender, area of residence and calendar period by means of the observed to expected (O/E) ratios. Results During the follow-up period, 4,633 (77%) subjects had not married. The marriage O/E ratios were 0.56 (95% CI: 0.51-0.61) and 0.70 (95% CI: 0.65-0.76) among men and women, respectively. Overall, 263 men had 367 liveborn children, and 473 women had 697 liveborn children. The female fertility O/E ratio was 0.57 (95% CI: 0.53-0.62) overall, and 1.08 (95% CI: 0.99-1.17) when analyses were restricted to married/cohabiting women Conclusions Childhood cancer survivors are less likely to marry and to have children than the general population, confirming the life-long impact of their previous disease on their social behavior and choices. The inclusion of counseling in the strategies of management and long-term surveillance of childhood cancer patients could be beneficial to survivors as they approach adulthood. ©2011 Ferrata Storti Foundation.
- Published
- 2011
35. LA CHIRURGIA NEI PAZIENTI AFFETTI DA TUMORI A CELLULE GERMINALI MALIGNI (tgcm) TESTICOLARI: COMPLIANCE ALLE LINEE GUIDA CHIRURGICHE E RISULTATI DELLO STUDIO COOPERATIVO ITALIANO
- Author
-
DALL'IGNA,P, TERENZIANI,M, SIRACUSA, Fortunato, PIVA,L, NANNI,L, CECCHETTO,G, DALL'IGNA,P, TERENZIANI,M, SIRACUSA,F, PIVA,L, NANNI,L, and CECCHETTO,G
- Subjects
TUMORI GERMINALI MALIGNI, CHIRURGIA PEDIATRICA ,Settore MED/20 - Chirurgia Pediatrica E Infantile ,ONCOLOGIA PEDIATRICA - Abstract
I tumori germinali maligni del testicolo rappresentano una evenienza rara. L'approccio chirurgico consiste nella orchiectomia radicale con eventuale esplorazione chirurgica dei linfonodi retroperitoneali doppo l'opportuna valutazione per imaging. vengono presentati i risultati di uno Studio Cooperativo Nazionale.
- Published
- 2011
36. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
- Author
-
Spreafico F, Gandola L, D'Angelo P, Terenziani M, Collini P, Bianchi M, Provenzi M, Indolfi P, Nantron M, Di Cataldo A, Marchianò A, Catania S, Fossati Bellani F, Piva L, AIEOP Wilms Tumor Working Group, PESSION, ANDREA, Spreafico F, Gandola L, D'Angelo P, Terenziani M, Collini P, Bianchi M, Provenzi M, Indolfi P, Pession A, Nantron M, Di Cataldo A, Marchianò A, Catania S, Fossati Bellani F, Piva L, and AIEOP Wilms Tumor Working Group.
- Subjects
Male ,Cancer Research ,Staging ,medicine.medical_treatment ,Gastroenterology ,Nephrectomy ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Stage (cooking) ,Prospective cohort study ,Child ,Lymph node ,Societies, Medical ,Radiation ,Radiotherapy Dosage ,Prognosis ,Combined Modality Therapy ,Kidney Neoplasms ,Wilms tumor ,Kidney tumors ,Radiotherapy ,medicine.anatomical_structure ,Oncology ,Italy ,Vincristine ,Child, Preschool ,Lymphatic Metastasis ,Dactinomycin ,Female ,medicine.drug ,medicine.medical_specialty ,Wilms Tumor ,Disease-Free Survival ,Internal medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Staging ,Chemotherapy ,business.industry ,Infant ,Wilms' tumor ,medicine.disease ,Surgery ,Radiation therapy ,Doxorubicin ,Neoplasm Recurrence, Local ,Kidney tumors, Lymph node, Radiotherapy, Staging, Wilms tumor ,business ,Follow-Up Studies - Abstract
PURPOSE: We analyzed whether the prognosis can differ among Wilms tumors (WT) labeled as Stage III according to currently adopted classification systems. METHODS AND MATERIALS: Patients with nonanaplastic Stage III WT consecutively registered in two Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials (CNR-92, TW-2003) were the subjects in the present analysis. The steady mainstay of therapy was primary nephrectomy, followed by three-drug chemotherapy with vincristine, dactinomycin, doxorubicin, and abdominal radiotherapy (RT). RESULTS: Ninety-nine WT patients met the criteria for classification as Stage III according to a revised version of the National Wilms Tumor Study-3 staging system (51 patients in CNR-92, 48 patients in TW-2003). Regional lymph nodes (LN) were not biopsied in 16 patients. After a median follow-up of 66 months, the 4-year disease-free survival (DFS) and overall survival (OS) rates were 85% ± 4% and 92% ± 3%, respectively, for the whole group. For 38 children with positive LN, the 4-year DFS rate was 73% ± 7%, as opposed to 98% ± 2% for the 45 children with Stage III WT according to the other criteria but with negative biopsied LN (p = 0.001). The subgroup with the worst prognosis consisted of children more than 2 years old with positive LN (DFS 67% ± 8%). A delay between surgery and RT > 30 days had an adverse impact on the abdominal tumor relapse rate. CONCLUSIONS: This study provides further evidence that Stage III tumors with LN metastases might be distinguished from WTs meeting the other criteria for classification as Stage III. The worse outcome of the former may warrant a prospective study on the effects of intensified therapy. A subclassification of Stage III tumors is discussed.
- Published
- 2010
37. Protocollo AIEOP Tumore di Wilms ( TW) 2003 : osservazioni preliminari
- Author
-
Spreafico F., Collini P., Piva L., Gandola L., Nantron M., Bianchi M., D'Angelo P., Indolfi P., Di Cataldo A., Terenziani M., Tamaro P., Provenzi M., Gambini C., Pucci A., Rizzo A., Santoro N., Martone A., Favre C., Federici S., Tettoni K., Miglionico L., Melchionda F., Barone A., Perotti D., Radice P., Fossati Bellani F., PESSION, ANDREA, Spreafico F., Collini P., Piva L., Gandola L., Nantron M., Pession A., Bianchi M., D'Angelo P., Indolfi P., Di Cataldo A., Terenziani M., Tamaro P., Provenzi M., Gambini C., Pucci A., Rizzo A., Santoro N., Martone A., Favre C., Federici S., Tettoni K., Miglionico L., Melchionda F., Barone A., Perotti D., Radice P., and Fossati - Bellani F.
- Published
- 2007
38. ALTERAZIONI DEL GENE BAX NEI TUMORI A CELLULE GERMINALI IN ETA’ PEDIATRICA: UN MARCATORE MOLECOLARE PROGNOSTICO?
- Author
-
ADDEO R, CASALE F, DANGEL V, CRISCI S, DI TULLIO MT, ROMANO MT, PETTINATO G, DONOFRIO V, MARTONE A, ALAGGIO R, BOLDRINI R, COLLINI P, TERENZIANI M, FUSCO C, INDOLFI P., LO CURTO, Margherita, ADDEO R, CASALE F, DANGEL V, CRISCI S, DI TULLIO MT, ROMANO MT, PETTINATO G, DONOFRIO V, MARTONE A, ALAGGIO R, BOLDRINI R, COLLINI P, LO CURTO M, TERENZIANI M, FUSCO C, and INDOLFI P
- Published
- 2005
39. OVARIAN SPARING SURGERY IN BILATERAL TERATOMAS: RESULTS FROM GCTM 2004
- Author
-
Virgone, C., Cecchetto, Giovanni, Terenziani, M., D’Angelo, P., Buffa, P., and Dall’Igna, P.
- Published
- 2013
40. STAGE I GONADAL GERM CELL TUMORS: OUTCOME AFTER THE SURVEILLANCE STRATEGY AS APPLIED IN THE AIEOP 2004 PROTOCOL
- Author
-
Terenziani, M, D’Angelo, P, Bisogno, Gianni, Boldrini, R, Cecchetto, Giovanni, Collini, P, Conte, M, De Pasquale MD, Indolfi, P, Inserra, A, Piva, L, Siracusa, F, and Spreafico, F.
- Published
- 2012
41. LOOKING FOR THE OPTIMAL THERAPY FOR STAGE I WILMS TUMOUR (WT). DATA FROM THE ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA (AIEOP) TW-2003 PROTOCOL
- Author
-
Spreafico, F, D’Angelo, P, Pession, A, Terenziani, M, DI CATALDO, Andrea, Gandola, L, Indolfi, P, Piva, L, Perotti, D, Provenzi, M, Bianchi, M, Nantron, M, Mariani, L, and Collini, P.
- Published
- 2012
42. IL TRATTAMENTO DEI TERATOMI BILATERALI DELL’OVAIO: RISULTATI DELLO STUDIO TCGM 2004
- Author
-
Virgone, C., Cecchetto, G., Inserra, A., Cesca, E., Buffa, P., Babbo, G., D’Angelo, P., Terenziani, M., and Dall’Igna, P.
- Published
- 2012
43. Sex cord stromal tumors of the ovary in children: a clinicopathological report from the Italian TREP project
- Author
-
Cecchetto, Giovanni, Ferrari, A, Bernini, G, Alaggio, Rita, Collini, P, Virgone, C, Terenziani, M, Dall'Igna, P, Cozza, R, Conte, M, Bisogno, Gianni, and Virgone, Calogero
- Subjects
Ovarian Neoplasms ,Adolescent ,Infant ,Combined Modality Therapy ,Survival Rate ,Bleomycin ,Treatment Outcome ,Child, Preschool ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Sex Cord-Gonadal Stromal Tumors ,Female ,Prospective Studies ,Cisplatin ,Child ,Etoposide - Abstract
Ovarian sex-cord stromal tumors (SCST) are rare in childhood and include a variety of neoplasms with different clinical features and biologic behavior. Aim of the analysis was to report the clinical findings and treatment results of a series of patients with SCST of the ovary, registered in a multi-institutional Italian network on rare tumors in children and adolescent between 2000 and 2009.Data on 23 patients, 5-176 months old, from 13 Centers were reviewed. All patients were grouped on the basis of the results of the first surgical approach, according to the Children Oncology Group staging system. A cisplatin based chemotherapy was recommended in patients with a localized disease, who had undergone an incomplete excision/initial biopsy, and in case of metastatic spread.A frequent symptom was abdominal pain; 9/23 cases had signs of hormonal secretion and two patients were hospitalized for acute pain following ovarian torsion. Twelve patients had a Juvenile-Granulosa Cell tumor, six a Sertoli-Leydig Cell tumor, three a Fibrothecoma, and two a Sclerosing-Stromal tumor. Twenty-one patients maintained the complete remission (follow-up: 9-91 months), 2 with a ST II Sertoli-Leydig Cell tumor relapsed and one of them died. Immonohistochemical studies could be done in 10 cases.Completeness of resection and histology were important prognostic factors; in our series the Sertoli-Leydig Cell tumor was the most aggressive variety. Hormonal signs (precocious puberty, telarca, menarche) were common in younger patients and led to an early diagnosis. Cisplatin based chemotherapy seemed to be effective for locally advanced tumors.
- Published
- 2011
44. Surgery in patients with testicular MGCT: compliance to surgical guidelines and results in the Italian Cooperative Study
- Author
-
Cecchetto, Giovanni, Piva, L, Inserra, A, Siracusa, F, Boschetti, L, D’Angelo, P, and Terenziani, M.
- Published
- 2011
45. 3410 Fertility status and preservation in chemo-naive adult female patients with high-grade sarcomas
- Author
-
Libertini, M., primary, Ottolina, J., additional, Giorgione, V., additional, Vailati, S., additional, Terenziani, M., additional, Casali, P.G., additional, Bertulli, R., additional, and Mangili, G., additional
- Published
- 2015
- Full Text
- View/download PDF
46. Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer
- Author
-
Terenziani, M., primary, Massimino, M., additional, Magazzù, D., additional, Gandola, L., additional, Capri, G., additional, Carcangiu, M.L., additional, Catania, S., additional, Di Russo, A., additional, Gennaro, M., additional, Meazza, C., additional, Podda, M., additional, Schiavello, E., additional, and Valagussa, P., additional
- Published
- 2015
- Full Text
- View/download PDF
47. Use of the Word “Cured” for Cancer Patients—Implications for Patients and Physicians: The Siracusa Charter
- Author
-
Tralongo, P., primary, Maso, L. Dal, additional, Surbone, A., additional, Santoro, A., additional, Tirelli, U., additional, Sacchini, V., additional, Pinto, C., additional, Crispino, S., additional, Ferraù, F., additional, Mandoliti, G., additional, Tonini, G., additional, Russo, A., additional, Santini, D., additional, Madeddu, A., additional, Panebianco, V., additional, Pergolizzi, S., additional, Respini, D., additional, Rolfo, C., additional, Bongiovanni, M., additional, De Lorenzo, F., additional, Spatola, C., additional, Di Raimondo, F., additional, Terenziani, M., additional, Peeters, M., additional, and Castoro, C., additional
- Published
- 2015
- Full Text
- View/download PDF
48. Why Wilms tumour diagnosed in children
- Author
-
Dangelo, P, DI CATALDO, Andrea, Bianchi, M, Bisogno, G, Catania, S, Collini, P, Indolfi, P, Marchianò, A, Melchionda, F, Mosa, C, Nantron, M, Perotti, D, Pession, A, Piva, L, Provenzi, M, Terenziani, M, and Spreafico, F.
- Published
- 2010
49. Loss of heterozigosity at chromosome 1p identifies a poorer prognosis Wilms tumour subgroup: results from Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) TW 2003 protocol
- Author
-
Spreafico, F, Gamba, B, Mariani, L, Collini, P, Bianchi, M, Dangelo, P, DI CATALDO, Andrea, Indolfi, P, Nantron, M, Pession, A, Provenzi, M, Terenziani, M, Radice, P, Mattana, F, and Perotti, D.
- Published
- 2010
50. Bilateral Wilms tumour (stage V): a report from the Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) Wilms tumour 2003 cooperative protocol
- Author
-
Terenziani, M, Indolfi, P, Ardissino, G, Bianchi, M, Biasoni, D, Catania, S, Collini, P, Dangelo, P, DI CATALDO, Andrea, Gandola, L, Marchianò, A, Nantron, M, Perotti, D, Pession, A, Piva, L, Provenzi, M, Rizzo, A, and Spreafico, P.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.